STOCK TITAN

Rhythm Pharmaceuticals, Inc. - $RYTM STOCK NEWS

Welcome to our dedicated page for Rhythm Pharmaceuticals news (Ticker: $RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceuticals stock.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is a commercial-stage biopharmaceutical company based in Boston, MA, focused on transforming the lives of patients and their families living with rare neuroendocrine diseases. The company's core mission is to develop and commercialize peptide therapeutics for treating gastrointestinal diseases and genetic deficiencies that result in metabolic disorders.

At the heart of Rhythm's portfolio is setmelanotide (IMCIVREE®), an MC4 receptor agonist designed to treat hyperphagia and severe obesity caused by specific genetic conditions. Setmelanotide is already approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults and children aged 6 years and older with monogenic or syndromic obesity due to certain genetic deficiencies. The European Commission (EC) and the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) have also authorized setmelanotide for the treatment of obesity and hunger control associated with Bardet-Biedl syndrome (BBS) and other genetic deficiencies.

Rhythm is advancing a broad clinical development program for setmelanotide, including ongoing global Phase 3 trials for hypothalamic obesity. Recent achievements include the addition of a cohort of Japanese patients to this trial, with dosing expected to begin in the third quarter of 2024. The company has enrolled 120 patients in its pivotal Phase 3 trial, aiming to achieve top-line results by the first half of 2025.

In addition to setmelanotide, Rhythm is also advancing investigational MC4R agonists, such as RM-718, which targets hyperphagia and severe obesity without causing hyperpigmentation. The company recently dosed the first patients in a Phase 1 clinical trial for RM-718 and is committed to exploring its potential benefits.

Financially, Rhythm Pharmaceuticals is well-positioned with proceeds from recent financing and existing cash on-hand expected to fund operations into 2026. The company's global reach includes generating revenues from the United States, Germany, and other countries, with the majority coming from the U.S.

For more information, visit Rhythm's Investor Relations page or contact their corporate communications team.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.01%
Tags
none

FAQ

What does Rhythm Pharmaceuticals, Inc. specialize in?

Rhythm Pharmaceuticals specializes in developing and commercializing therapies for rare neuroendocrine diseases, focusing on peptide therapeutics for gastrointestinal and metabolic disorders.

What is setmelanotide (IMCIVREE®) used for?

Setmelanotide (IMCIVREE®) is used for chronic weight management in adults and children aged 6 years and older with monogenic or syndromic obesity due to genetic deficiencies.

Which regulatory bodies have approved setmelanotide?

Setmelanotide is approved by the U.S. FDA, the European Commission (EC), and the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) for treating obesity and hunger control associated with specific genetic conditions.

What are Rhythm Pharmaceuticals' recent achievements?

Recent achievements include adding a cohort of Japanese patients to their global Phase 3 trial for hypothalamic obesity and initiating a Phase 1 trial for RM-718.

Where is Rhythm Pharmaceuticals headquartered?

Rhythm Pharmaceuticals is headquartered at 855 Boylston Street, 11th Floor, Boston, MA, United States.

What is RM-718?

RM-718 is an investigational MC4R-specific agonist designed to reduce hyperphagia and severe obesity without causing hyperpigmentation. It is currently in Phase 1 clinical trials.

How is Rhythm Pharmaceuticals financially positioned?

Rhythm Pharmaceuticals has secured sufficient funding from recent financing and existing cash on-hand to support planned operations into 2026.

In which markets is setmelanotide available?

Setmelanotide is available in 14 markets, including the United States, and also generates revenue from Germany and other countries.

What are the limitations of using setmelanotide?

Setmelanotide is not indicated for patients with certain conditions and has specific contraindications, including serious hypersensitivity reactions.

What are common adverse reactions to setmelanotide?

Common adverse reactions include skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, and depression.

Rhythm Pharmaceuticals, Inc.

Nasdaq:RYTM

RYTM Rankings

RYTM Stock Data

2.55B
45.62M
0.54%
116.07%
16.93%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOSTON